Abstract
Ischemic stroke is one of the leading causes of death and morbidity worldwide, and systemic thrombolytic treatment is still the first-line therapy within 4.5 h from symptom onset. Selecting patients for treatment response is mandatory in any time window but challenging as well. The authors aim to support stroke physicians in their individual decision making. Besides evidence from clinical trials, some suggestions included here exclusively reflect the authors' opinions. This article presents clinical and imaging criteria of selecting patients reasonably, offering causal therapy to a growing number of patients.
© 2012 New York Academy of Sciences.
MeSH terms
-
Acute Disease
-
Biomarkers
-
Brain Ischemia / diagnostic imaging
-
Brain Ischemia / drug therapy*
-
Brain Ischemia / pathology
-
Cerebral Angiography
-
Cerebral Infarction / pathology
-
Cerebral Infarction / prevention & control
-
Clinical Trials, Phase III as Topic
-
Diffusion Magnetic Resonance Imaging / methods*
-
Fibrinolytic Agents / therapeutic use*
-
Humans
-
Meta-Analysis as Topic
-
Middle Cerebral Artery / diagnostic imaging
-
Multicenter Studies as Topic
-
Patient Selection*
-
Practice Guidelines as Topic
-
Randomized Controlled Trials as Topic
-
Reperfusion Injury / prevention & control
-
Risk Assessment
-
Thrombolytic Therapy*
-
Time Factors
-
Tomography, X-Ray Computed / methods*
-
Treatment Outcome
Substances
-
Biomarkers
-
Fibrinolytic Agents